A few days ago, sponsored by the Institute of Clinical Pharmacology of Central South University, co-organized by the Wuhan Clinical Laboratory Center and the Joint Office of Wuhan Medical and Health Society, the World Health Expo Individualized Medicine Summit Forum and the 14th Individualized Medicine Xiangya Forum were held in Wuhan, Hubei, and the 14th training course of the Individualized Medical Testing Training Base of the National Health Commission was also held at the same time. DCHeal brought its overall solution for pharmacogenetic testing, iCMDB knowledge base, multimodal scientific research platform and other products to the conference, which received extensive attention from the guests.
Pharmacogenetic testing empowers the transformation and upgrading of clinical personalized pharmacy service models
In this meeting, Wu Jinhu, director of Wuhan Third Hospital, delivered a speech entitled "Exploration of Individualized Service Model of Clinical Pharmacy", which clearly pointed out the multiple challenges faced by the current clinical pharmacy service model in mainland China:
1. The service model is lagging behind: the mainland has not yet built a scientific and reasonable pharmaceutical service system.
2. Weak technical means: The technical support related to clinical individualized medication is still insufficient.
3. Marginalization of the role of pharmacists: Clinical pharmacists are less involved in the drug treatment process.
4. Lack of awareness and attention: The hospital decision-makers do not have enough understanding of the importance and value of clinical pharmacy.
Despite the above problems, with the continuous introduction of relevant policies in recent years to guide and promote the development direction of clinical pharmacy service model, mainland China has shown a positive trend in the innovation and exploration of clinical personalized pharmacy service model.
Pharmacogenomics is the key to personalized medicine and an important part of clinical personalized pharmacy services. Pharmacogenomics takes drug efficacy and safety as the main goal, and it is an important method to improve the level of rational drug use by studying the genetic characteristics of the differences caused by the metabolism of drugs in vivo and the different responses of different patients to drugs caused by gene variations. Pharmacogenomics breaks the traditional "one in a thousand" drug delivery model, and uses gene polymorphisms to "tailor drugs" to patients, so as to improve drug efficacy, shorten the course of disease, save costs, and reduce the incidence of adverse drug reactions
Shenzhou Medical's overall solution for pharmaceutical genetic testing
Focusing on the field of personalized medication for cardiovascular and cerebrovascular diseases, psychiatric diseases, tumors and other fields, DCHeal's pharmacogenetic testing focuses on the clinical application of pharmacogenomics based on the real-time evidence-based annotation and interpretation of the knowledge base iCMDB of localized clinical omics, and provides individualized precision medication overall solutions based on Clair, a pharmacogenomic data analysis platform. On the one hand, it can provide decision support for clinicians and pharmacists, and on the other hand, it can help patients choose the right drug to maximize drug efficacy and minimize drug risks. In conclusion, DCM's overall solution for pharmacogenetic testing has strongly promoted the innovation and upgrading of the clinical personalized pharmacy service model in mainland China, and laid a solid foundation for the realization of precision and personalization of medical services.
The overall solution of pharmacogenetic testing
Multimodal technology drives the process of advanced pharmaceutical genomics
Academician Zhou Honghao of Central South University mentioned in the report that pharmacogenomics has entered the third milestone stage, and machine learning and artificial intelligence technology play a key role. In clinical practice, although genetic information plays an important role, in order to achieve accuracy, it is necessary to integrate multi-omics data (such as genome, transcriptome, epigenome, proteome, metabolome, etc.) and multimodal clinical data (such as imaging and physiological indicators) to conduct in-depth comprehensive modeling and analysis, in order to achieve a comprehensive and multi-level understanding of the patient's condition and effectively drive the precise implementation of individualized drug treatment.
Shenzhou Medical Multimodal Research Platform
With the rapid development of big data technology, the continuous breakthrough of artificial intelligence technology, and the advent of the era of digital intelligent medicine, the development of health care big data application will bring profound changes to the health care model. In recent years, multimodal clinical data fusion research has become a research hotspot at home and abroad, and multimodal research directions in the field of pharmacogenomics, tumor diagnosis and treatment, neurological diseases and other complex diseases have been continuously explored, aiming to comprehensively improve the diagnosis and treatment quality of complex diseases, and gradually promote the realization of digital, intelligent and accurate diagnosis and treatment. Shenzhou Medical, which has been deeply involved in medical big data for many years, has jointly tackled key technical problems, and built a multi-modal big data research platform with multi-modal big data as the foundation and multi-dimensional artificial intelligence technology as the core.
Multimodal medical research analysis
The research value of the platform for clinical pharmacogenomics is mainly reflected in the following three aspects: through the fusion modeling and analysis of data from multiple medical modalities, the study of individualized drug doses, the study of precision drug efficacy, and the study of adverse drug reactions. Through the fusion modeling and analysis of multi-dimensional heterologous structure data, an accurate medical research model is constructed, which provides a "powerful weapon" for pharmacogenomics clinical scientific research.
DCHeal's multimodal medical research platform has completed a number of technological breakthroughs and published academic results in journals such as frontiers, nature communications, and JMIR. The platform has been applied in well-known hospitals such as Nanfang Hospital of Southern Medical University and Chinese People's Liberation Army General Hospital, and has completed more than 50 cross-modal studies, becoming an important supporting force for multimodal medical research in large teaching hospitals, accelerating hospital scientific research output and helping the high-quality development of medical research.
Digital State Healthcare's multimodal medical research academic achievements
DCHeal's precision medicine platform
DCHeal's precision medicine platform focuses on tumors, genetic diseases & rare diseases, cardiovascular and cerebrovascular diseases, and has oncology, pharmacogenomics, genetic diseases & rare disease genetic testing services to create a precision diagnosis and treatment ecological service system. In the direction of intelligent systems, it is equipped with three international standard precision medicine knowledge bases (iCMDB), Origo tumor automatic reporting system, Omicsta omics data storage and statistical platform, multi-omics clinical special disease research platform, and intelligent biobank platform, which comprehensively empower clinical precision diagnosis and treatment, hospital big data construction, medical research and drug research and development.
The DCHeal precision medicine platform team has project members with professional knowledge and rich experience in medicine, bioinformatics, IT and other fields, which can fully support clinical medical testing and the full chain of services built by intelligent data systems.